Medical Developments International Limited MVP
ASX · Australia · Health Technology
AUD 0.4250-0.01 (-2.30%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Strong Penthrox demand and improved cash flow offset respiratory weakness and FX headwinds.
As Australian shares edge up with a 0.4% advance, the market is showing resilience amid global uncertainties and potential interest rate decisions. In this climate, investors often turn their attention to penny stocks—companies that may be smaller or newer but can offer intriguing opportunities when backed by solid financials. Despite their vintage name, these stocks continue to capture interest for their potential to uncover hidden value and growth prospects in the ever-evolving market...
Medical Developments International Ltd (MDDVF) reports an 8% revenue increase, driven by a robust 18% growth in pain management, while facing a 10% decline in the respiratory segment.
Seasoned global pharmaceutical executive, Mr Brent MacGregor, joins Vaxxas Board to accelerate self-administered HD-MAP vaccines for global use;SPRIM Global Investment’s Co-Founder and Managing Partner, Mr Michael Shleifer appointed Board Observer following recent ~$90 million financing. BRISBANE, Australia and CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology company Vaxxas Pty Ltd, today announced the appointment of Mr Brent MacGregor as Independent Non-Executive Dir
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.